Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
- Type
- Retraction
- Notice date
- 7/26/2023 0:00
- Journal
- Disease Markers
- Publisher
- Hindawi
- Notice DOI
- 10.1155/2023/9791613
- Original paper DOI
- 10.1155/2022/6957580
Reasons
- Concerns/Issues about Data
- Concerns/Issues about Results and/or Conclusions
- Concerns/Issues about Referencing/Attributions
- Concerns/Issues about Peer Review
- Investigation by Journal/Publisher
- Investigation by Third Party
- Computer-Aided Content or Computer-Generated Content
- Unreliable Results and/or Conclusions